» Articles » PMID: 23233863

EGFR Signaling Pathway and Related-miRNAs in Age-related Diseases: the Example of MiR-221 and MiR-222

Overview
Journal Front Genet
Date 2012 Dec 13
PMID 23233863
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Presently, neurodegenerative diseases and cancer are the most clinically problematic age-related diseases worldwide. Although being distinct disorders, their developments share common cellular mechanisms. Oncogenesis and neurodegeneration arise from the deregulation of signaling pathways, as a consequence of the resulting imbalance in cellular homeostasis. The epidermal growth factor receptor (EGFR) belongs to an important cellular signaling pathway, which regulates proliferation, differentiation, cell cycle and migration. As transcriptional targets of EGFR, the microRNAs-221/222 (miR-221/222) are important expression regulators. Dysfunctions in their networks are associated with cellular disruptions. The transcriptional activation of these microRNAs (miRNAs) seems to be involved in cell cycle, apoptosis, metastization, and in the acquisition of resistance to therapies. The up-regulation of miR-221/222 is associated with increased expression levels of matrix metalloproteinases (MMPs) and repression of cell cycle inhibitors, which are key molecules in oncogenesis and neurodegeneration processes. The interaction loop between proliferative signaling pathways and miRNA expression could reveal new targets for controlling the molecular behavior of age-related diseases.

Citing Articles

Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer.

Fang Y, Zhang Q, Chen Z, Guo C, Wu J Aging (Albany NY). 2024; 16(1):322-347.

PMID: 38189813 PMC: 10817385. DOI: 10.18632/aging.205370.


Identification and comprehensive analysis of epithelial-mesenchymal transition related target genes of miR-222-3p in breast cancer.

Fang Y, Zhang Q, Chen C, Chen Z, Zheng R, She C Front Oncol. 2023; 13:1189635.

PMID: 37546414 PMC: 10400091. DOI: 10.3389/fonc.2023.1189635.


Mechanisms underlying microRNA-222-3p modulation of methamphetamine-induced conditioned place preference in the nucleus accumbens in mice.

Shang Q, Wang J, Xi Z, Gao B, Qian H, An R Psychopharmacology (Berl). 2022; 239(9):2997-3008.

PMID: 35881147 DOI: 10.1007/s00213-022-06183-9.


Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer's Disease.

Arora T, Prashar V, Singh R, Barwal T, Changotra H, Sharma A Mol Neurobiol. 2022; 59(10):6107-6124.

PMID: 35867206 DOI: 10.1007/s12035-022-02950-z.


The Study of Cerebrospinal Fluid microRNAs in Spinal Cord Injury and Neurodegenerative Diseases: Methodological Problems and Possible Solutions.

Baichurina I, Valiullin V, James V, Rizvanov A, Mukhamedshina Y Int J Mol Sci. 2022; 23(1).

PMID: 35008540 PMC: 8744986. DOI: 10.3390/ijms23010114.


References
1.
Teixeira A, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A . Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res. 2008; 14(11):3367-71. DOI: 10.1158/1078-0432.CCR-07-5119. View

2.
Attar R, Takimoto C, Gottardis M . Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res. 2009; 15(10):3251-5. DOI: 10.1158/1078-0432.CCR-08-1171. View

3.
Kwak E, Jankowski J, Thayer S, Lauwers G, Brannigan B, Harris P . Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006; 12(14 Pt 1):4283-7. PMC: 3807136. DOI: 10.1158/1078-0432.CCR-06-0189. View

4.
Sun T, Wang Q, Balk S, Brown M, Lee G, Kantoff P . The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009; 69(8):3356-63. PMC: 2703812. DOI: 10.1158/0008-5472.CAN-08-4112. View

5.
Sharma S, Bell D, Settleman J, Haber D . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-81. DOI: 10.1038/nrc2088. View